Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM) AI Stock Analysis

• Market Cap: ₹644.44M
• Dividend Yield: N/A
• Average Volume (3M): 6.87K
• Price to Earnings (P/E): 23.0
• Beta (1Y): 1.17
• Revenue Growth: 36.76%
• EPS Growth: 433.63%
• Country: IN
• Employees: 26
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.05
• Shares Outstanding: 16,273,800
• 10 Day Avg. Volume: 7,559
• 30 Day Avg. Volume: 6,869
• PEG Ratio: -5.50
• Price to Book (P/B): 3.72
• Price to Sales (P/S): 2.09
• P/FCF Ratio: -34.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: ₹41.00 ▲(8.70% Upside)

Biofil Chemicals & Pharmaceuticals Ltd. faces challenges with declining revenue and cash flow issues, reflected in a moderate financial performance score. The technical analysis indicates bearish momentum, further impacting the overall score. The valuation is moderate, but the lack of a dividend yield reduces appeal for certain investors.

Positive Factors

Operational Efficiency

Operational efficiency and a solid balance sheet suggest the company can sustain its operations effectively, supporting long-term stability.

Strategic Partnerships

Strategic partnerships enhance revenue streams and market reach, providing a competitive edge and fostering sustainable growth.

Product Innovation

Investment in R&D for new products can drive future growth and market expansion, ensuring the company remains competitive in evolving markets.

Negative Factors

Revenue Decline

A decline in revenue suggests market challenges that could affect long-term growth prospects and financial health if not addressed.

Cash Flow Challenges

Negative cash flow growth indicates potential liquidity issues, which could limit the company's ability to invest in growth opportunities.

Profitability Volatility

Volatile profitability can undermine investor confidence and affect the company's ability to sustain long-term financial performance.

Biofil Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic dippers and caps. It also provides job work service for manufacturing of pharmaceuticals. The company was incorporated in 1985 and is based in Indore, India.

How the Company Makes Money

BIOFILCHEM generates revenue primarily through the sale of its chemical intermediates and APIs to pharmaceutical companies, agricultural firms, and other industrial clients. The company has established key revenue streams by forming strategic partnerships with major pharmaceutical manufacturers, allowing it to supply essential raw materials for drug development and production. Additionally, BIOFILCHEM engages in contract manufacturing, providing tailored solutions and formulations for clients, which further diversifies its income sources. The company also invests in research and development to innovate new products, creating opportunities for growth in emerging markets. By maintaining high standards of quality and compliance, BIOFILCHEM secures long-term contracts and fosters customer loyalty, contributing significantly to its overall earnings.

Biofil Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

Biofil Chemicals & Pharmaceuticals Ltd. shows operational efficiency and a solid balance sheet with a moderate debt-to-equity ratio. However, fluctuating revenue, profitability, and cash flow challenges highlight potential concerns.

Income Statement

Biofil Chemicals & Pharmaceuticals Ltd. has shown fluctuating revenue and profitability over recent years. The gross profit margin has generally remained stable, but net profit margin has seen some volatility. Revenue has decreased in the latest year, indicating potential market challenges. However, the company has managed to maintain positive EBIT and EBITDA margins, suggesting operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a moderate debt-to-equity ratio, indicating manageable leverage. The equity ratio is strong, reflecting a solid capital structure with a reasonable level of shareholder equity. Return on equity has been positive, though showing some variability, highlighting potential for investor returns.

Cash Flow

Cash flow performance has been mixed, with recent periods showing negative free cash flow growth, driven by high capital expenditures relative to generated cash. The operating cash flow to net income ratio indicates some inconsistency in cash generation from operations, suggesting potential liquidity challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	313.91M	334.02M	400.35M	300.35M	223.82M	357.50M
Gross Profit	19.26M	20.91M	25.28M	25.63M	28.66M	33.23M
EBITDA	36.53M	11.53M	13.06M	12.65M	14.83M	23.99M
Net Income	28.00M	5.58M	7.09M	5.60M	6.98M	12.41M
Balance Sheet
Total Assets	0.00	509.60M	470.83M	314.06M	187.32M	332.38M
Cash, Cash Equivalents and Short-Term Investments	2.55M	2.55M	22.84M	377.00K	1.45M	4.41M
Total Debt	0.00	4.71M	4.39M	5.22M	4.65M	4.30M
Total Liabilities	-187.82M	321.79M	288.80M	141.04M	18.95M	171.09M
Stockholders Equity	187.82M	187.82M	182.03M	173.01M	168.38M	161.29M
Cash Flow
Free Cash Flow	0.00	-20.24M	23.71M	-1.22M	-2.90M	5.44M
Operating Cash Flow	0.00	-19.24M	23.94M	-1.12M	-2.20M	11.11M
Investing Cash Flow	0.00	-1.00M	-229.00K	-106.00K	-699.00K	-961.00K
Financing Cash Flow	0.00	-45.00K	-1.25M	151.00K	-58.00K	-8.30M

Biofil Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 37.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOFILCHEM, the sentiment is Negative. The current price of 37.72 is below the 20-day moving average (MA) of 39.04, below the 50-day MA of 40.36, and below the 200-day MA of 44.82, indicating a bearish trend. The MACD of -0.65 indicates Positive momentum. The RSI at 34.98 is Neutral, neither overbought nor oversold. The STOCH value of 29.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BIOFILCHEM.

Biofil Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALPHARMA	58 Neutral	₹1.30B	15.34	―	1.60%	-9.07%	5.36%
BIOFILCHEM	55 Neutral	₹644.44M	23.02	―	―	36.76%	433.63%
INDSWFTLTD	53 Neutral	―	―	―	―	2.59%	1891.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VAISHALI	49 Neutral	₹973.30M	―	―	―	18.35%	-154.65%
MANGALAM	45 Neutral	₹577.10M	―	―	―	-24.55%	-310.57%
LASA	43 Neutral	₹585.18M	-1.77	―	―	-20.40%	-59.20%

Biofil Chemicals & Pharmaceuticals Ltd. Corporate Events

Biofil Chemicals Announces Virtual AGM and E-Voting

Biofil Chemicals & Pharmaceuticals Ltd. has announced the publication of a newspaper advertisement regarding its upcoming 40th Annual General Meeting (AGM) scheduled for September 27, 2025. The meeting will be conducted via video conferencing, and remote e-voting facilities will be available for shareholders. This move aligns with regulatory compliance and aims to facilitate shareholder participation, reflecting the company’s commitment to transparency and modern governance practices.